AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportRecursion Pharmaceuticals vs Abridge
Recursion Pharmaceuticals
VS
Abridge
Verdict by Category
Detailed category analysis is not available for this comparison.
Detailed Comparison
Feature
Recursion Pharmaceuticals
Abridge
Pricing
CustomRecursion operates through three revenue streams: pharma collaboration agreements, data licensing, and its own internal drug pipeline.
Pharma partnerships (Roche/Genentech, Sanofi) are structured as multi-year agreements with upfront payments and milestone-based payments tied to program progress. Recursion has earned $500M+ in cumulative milestones to date, with $134M from Sanofi alone.
Data licensing allows external researchers and pharma companies to access Recursion's proprietary biology maps and phenomics datasets for their own target discovery programs.
Recursion's own clinical programs (REC-4881, REC-1245, REC-4539) will generate revenue through future partnering, co-development, or commercialization deals as they advance through clinical trials. Total 2025 revenue: $74.7M. Contact Recursion through recursion.com for partnership inquiries.
EnterpriseAbridge does not publish pricing and sells exclusively through enterprise contracts with health systems and hospital groups; there is no self-serve signup or individual-clinician plan. Third-party market analyses and reseller estimates place costs at roughly $200-$800+ per provider per month depending on integration depth (Epic, Oracle Health, or athenahealth), contract scale, and support level, with some estimates for full enterprise rollouts running $600-$1,200+ per provider per month. Implementation typically includes a multi-week to multi-month pilot and IT integration phase before system-wide deployment.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare Tools
Summary
AI-native drug discovery OS with industrial-scale automated labs and $500M+ in pharma partnerships
Ambient AI that turns clinical conversations into ready-to-sign notes
Recursion Pharmaceuticals Pros & Cons
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Abridge Pros & Cons
Pros
- Best in KLAS for Ambient AI two years running (2025 and 2026)
- Largest independent peer-reviewed study of any ambient AI scribe (NEJM AI, 1,300+ clinicians)
- Deep, native Epic integration across Haiku, Canto, and Hyperdrive
- Broad specialty coverage (55+) across outpatient, inpatient, and ED settings
- Strong enterprise security posture: HIPAA, SOC 2 Type II, ISO 27001
Cons
- No public pricing, free trial, or self-serve signup for individual clinicians
- Enterprise-only sales process that can take months to complete
- Reported documentation error rates (including some hallucinated content) still require clinician review
- No built-in patient communication, scheduling, or billing automation
- Not a realistic option for solo practitioners or small group practices